|Mr. Marc Voigt||CEO, CFO, Chief Bus. Officer & Exec. Director||352.04k||N/A||1973|
|Ms. Deanne Miller||COO, Gen. Counsel & Joint Company Sec.||216.06k||N/A||1977|
|Dr. Frederic Triebel||Chief Scientific Officer & Chief Medical Officer||215.29k||N/A||1955|
|Ms. Indira Naidu||Joint Company Sec.||N/A||N/A||N/A|
|Mr. Christian Mueller||Director of Clinical Devel. & Regulatory Affairs||N/A||N/A||N/A|
|Mr. Shengfei Fang||Fin. Director & Assistant Company Sec.||N/A||N/A||N/A|
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Âeftilagimod alpha' or Âefti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Immutep Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.